(Fighting against New Coronary Pneumonia) National Health Commission: Vaccination will be carried out on a large scale for the elderly over 60 years old
China News Agency, Beijing, March 21 (Reporter Li Chun) He Qinghua, first-level inspector of the CDC of the National Health Commission of China, introduced on the 21st that China will carry out large-scale vaccination of the elderly over 60 years old.
On the same day, the Joint Prevention and Control Mechanism of the State Council of China held a press conference to introduce the safety and effectiveness of the new coronavirus vaccine.
Regarding the vaccination situation of people over 60 years old, He Qinghua introduced at the meeting that some areas have begun to vaccinate the new crown vaccine for people over 60 years old with better physical conditions under the premise of fully assessing their health conditions and the risk of infection.
At the same time, vaccine research and development units are also accelerating research and development. After clinical trials have obtained sufficient safety and effectiveness data, they will carry out large-scale vaccination of the elderly over 60 years old.
Liu Peicheng, Director of Branding and Public Relations of Beijing Kexing Company, introduced at the press conference that day that the company's new crown inactivated vaccine Kellyf has been successfully obtained in nearly 30 countries including China, Chile, Brazil, and Turkey since December last year. For batch use, up to now, including China, more than 70 million doses of Kellyve have been inoculated globally.
He pointed out that due to the specific circumstances of the epidemic, many countries have prioritized people over 60 years of age for vaccination, especially in some countries, starting vaccination from the highest age group.
Liu Peicheng said that based on the situation of vaccinations in the first- and second-stage clinical elderly group of Clareford in China and the feedback of large-scale use abroad, the incidence of adverse reactions to the vaccine in the elderly group is relatively low, compared with the situation in the adult group similar.
So far, no abnormalities related to the vaccine have been monitored.
(Finish)